Ofra Maimon
Impact in
-
- Neuroblastoma Research and Treatments
-
- Cancer, Hypoxia, and Metabolism
Papers in
- Oncology 8
- Cancer Risks and Factors 2
- Cancer Cells and Metastasis 2
- HER2/EGFR in Cancer Research 2
-
- Neuroendocrine Tumor Research Advances 6
- Co-authors
- Amichay Meirovitz (11 shared papers)David J. Gross (6 shared papers)Simona Grozinsky‐Glasberg (8 shared papers)Grace Kong (2 shared papers)Michael S. Hofman (2 shared papers)Rodney J. Hicks (2 shared papers)Jason Callahan (1 shared paper)David A. Pattison (1 shared paper)
- Journals
- Anticancer Research (3 papers)Frontiers in Oncology (2 papers)Biomedicines (1 paper)Journal of Thoracic Oncology (1 paper)Frontiers in Cell and Developmental Biology (1 paper)
- Partner nations
- IsraelUnited StatesAustralia
In The Last Decade
Ofra Maimon
23 papers receiving 312 citations
Peers
Comparison fields: 5 of 53
- Neurology 78
- Cancer Research 73
- Endocrinology, Diabetes and Metabolism 67
- Oncology 100
- Epidemiology 116
Countries citing papers authored by Ofra Maimon
This map shows the geographic impact of Ofra Maimon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ofra Maimon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ofra Maimon more than expected).
Fields of papers citing papers by Ofra Maimon
This network shows the impact of papers produced by Ofra Maimon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ofra Maimon. The network helps show where Ofra Maimon may publish in the future.
Co-authors
The 25 scholars most cited alongside Ofra Maimon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 125 | |
| 2 | 2019 | 50 | |
| 3 | 2018 | 20 | |
| 4 | 2024 | 12 | |
| 5 | The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer. | 2013 | 11 |
| 6 | 2013 | 11 | |
| 7 | 2020 | 10 | |
| 8 | 2022 | 9 | |
| 9 | 2023 | 9 | |
| 10 | 2020 | 8 | |
| 11 | 2022 | 7 | |
| 12 | 2020 | 7 | |
| 13 | 2023 | 6 | |
| 14 | 2021 | 6 | |
| 15 | 2021 | 6 | |
| 16 | 2024 | 4 | |
| 17 | 2019 | 4 | |
| 18 | 2021 | 3 | |
| 19 | 2023 | 2 | |
| 20 | 2022 | 2 |
About Ofra Maimon
Ofra Maimon is a scholar working on Oncology, Epidemiology, Cancer Research, Molecular Biology and Surgery, having authored 25 papers that have together received 316 indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (6 papers), Cancer Genomics and Diagnostics (2 papers), Cancer Risks and Factors (2 papers), Cancer, Stress, Anesthesia, and Immune Response (2 papers), Breast Cancer Treatment Studies (2 papers), Cancer Cells and Metastasis (2 papers), Adrenal and Paraganglionic Tumors (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Neurology (78 citations), Cancer Research (73 citations), Endocrinology, Diabetes and Metabolism (67 citations), Oncology (100 citations) and Epidemiology (116 citations). Ofra Maimon has collaborated with scholars based in Israel, United States and Australia. Frequent co-authors include Amichay Meirovitz, David J. Gross, Simona Grozinsky‐Glasberg, Grace Kong, Michael S. Hofman, Rodney J. Hicks, Jason Callahan, David A. Pattison, Tamar Peretz and Luna Kadouri. Their work appears in journals such as Anticancer Research, Frontiers in Oncology, Biomedicines, Journal of Thoracic Oncology and Frontiers in Cell and Developmental Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.